急性缺血性卒中延长窗静脉溶栓的研究间异质性:18项随机对照试验的荟萃分析
该研究系统检索并荟萃分析了15项研究(含18项随机对照试验、共5168例患者),评估发病4.5至24小时内静脉溶栓的疗效与安全性。结果显示,静脉溶栓可改善90天功能结局(mRS 0-1:40.3% vs 33.2%,RR 1.21),但症状性颅内出血风险升高(3.2% vs 1.4%,RR 1.90),90天死亡率无显著增加;荟萃回归提示血管内取栓背景是研究间异质性的主要来源。
要点
- 延长窗静脉溶栓改善90天功能结局,mRS 0-1的NNT为14。
- 症状性颅内出血风险升高(RR 1.90),但90天死亡率未增加。
- 取栓背景是研究间异质性的主要驱动因素,解释66%-100%的试验间方差。
核心结论
- 发病4.5至24小时内对存在可挽救组织的急性缺血性卒中患者行静脉溶栓可改善90天功能结局且不增加死亡率。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Cochrane Library和ClinicalTrials.gov(自建库至2026年2月)。
- 纳入比较末次已知正常4.5小时后静脉溶栓与对照的随机对照试验或个体患者数据荟萃分析。
- 主要分析纳入15项研究、代表18项随机对照试验、共5168例患者。
- 18项随机对照试验中11项要求高级灌注成像或DWI/FLAIR不匹配确认可挽救组织,其余7项允许基于非增强CT/CT血管成像选择。
- 采用多变量荟萃回归同时建模溶栓药物、血管内取栓背景与梗死区域。
主要发现
- 90天极佳功能结局(mRS 0-1)为40.3% vs 33.2%,RR 1.21(95%CI 1.13-1.30,p<0.001),NNT=14。
- 90天良好功能结局(mRS 0-2)为54.5% vs 50.1%,RR 1.09(95%CI 1.04-1.15,p<0.001),NNT=23。
- 全mRS谱系残疾改善的common OR为1.18(95%CI 1.07-1.32,p=0.004)。
- 症状性颅内出血为3.2% vs 1.4%,RR 1.90(95%CI 1.28-2.84,p=0.002),NNH=57。
- 90天死亡率为13.7% vs 13.0%,RR 1.04(95%CI 0.92-1.18,p=0.53)。
临床怎么用
- 对发病4.5至24小时、存在可挽救组织且取栓不可及的中重度急性缺血性卒中患者,可考虑静脉溶栓。
- 获益在取栓不可及环境下更严重卒中的患者中似乎最大。
- 决策时需权衡功能获益与症状性颅内出血风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: IV thrombolysis (IVT) is the standard-of-care evidence-based treatment of eligible patients with acute ischemic stroke (AIS) within 4.5 hours of symptom onset. Emerging evidence supports its use beyond this time window, leading to expanded recommendations for selected patients presenting between 4.5 and 24 hours. We performed a systematic review and meta-analysis to evaluate IVT in the 4.5- to 24-hour window and to explore sources of between-study heterogeneity. METHODS: We searched MEDLINE, Cochrane Library, and ClinicalTrials.gov from inception through February 2026. Eligible studies were randomized controlled trials (RCTs) or individual patient-data meta-analyses of RCTs comparing IVT with control in patients with AIS presenting beyond 4.5 hours from last known well. The primary outcome was excellent functional recovery, defined as a modified Rankin Scale (mRS) of 0-1 at 90 days. Secondary outcomes included functional independence (mRS of 0-2 at 90 days); change in mRS disability, quantified as the common odds ratio (OR) for a 1-point improvement across the full ordinal mRS distribution (ordinal analysis); and safety measures such as 90-day mortality and symptomatic intracranial hemorrhage (sICH). Risk ratios (RRs) with 95% CIs were pooled. Multivariable meta-regression simultaneously modeled thrombolytic agent, endovascular thrombectomy context, and territory to disentangle confounded predictors. RESULTS: Fifteen studies representing 18 RCTs and encompassing 5,168 patients were included in the primary analysis. Of the 18 included RCTs, 11 required advanced perfusion imaging (CTP or MRP mismatch) or diffusion-weighted imaging/fluid-attenuated inversion recovery mismatch to confirm salvageable tissue; the remaining 7 permitted noncontrast CT/CT angiography-based selection. IVT significantly improved excellent functional outcome at 90 days (mRS 0-1; 40.3% vs 33.2%, RR 1.21; 95% CI 1.13-1.30; p < 0.001; number needed to treat [NNT] = 14) and good functional outcome (mRS 0-2; 54.5% vs 50.1%, RR 1.09; 95% CI 1.04-1.15; p < 0.001; NNT = 23). IVT was associated with significantly greater odds of reduced disability across the full mRS spectrum (common OR 1.18; 95% CI 1.07-1.32; p = 0.004). IVT increased the risk of sICH (3.2% vs 1.4%; RR 1.90; 95% CI 1.28-2.84; p = 0.002; number needed to harm = 57) but did not increase 90-day mortality (13.7% vs 13.0% RR 1.04; 95% CI 0.92-1.18; p = 0.53). Meta-regression showed that thrombectomy (β = -0.275, p = 0.012 for mRS shift; β = -0.186, p = 0.032 for mRS 0-2) is the primary driver of between-study heterogeneity, explaining 66%-100% of intertrial variance. DISCUSSION: Extended-window IVT improves functional outcomes across a wider spectrum of stroke subgroups than previously recognized. The benefit seems greatest for patients with more severe strokes in settings where thrombectomy is unavailable, providing the evidence base for offering a critical reperfusion strategy for the substantial proportion of patients worldwide who lack timely access to thrombectomy. CLASSIFICATION OF EVIDENCE: This study provides American Academy of Neurology Class I evidence that IVT administered 4.5-24 hours after moderate-to-severe AIS onset in patients with salvageable tissue, where thrombectomy is not readily available, improves functional outcome at 90 days without increasing mortality.
引用
- Doheim MF, Al-Qudah AM, Singh R, et al. Exploring Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis of 18 Randomized Controlled Trials. Neurology. 2026. PMID: 42475651. doi:10.1212/WNL.0000000000218331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。